anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The investigators will seek approval from Mayo Clinic and Arizona State University Institutional Review Board to recruit 30 type 1 diabetes adult outpatients using insulin pumps and continuous glucose monitoring system from the Endocrinology Clinic at Mayo Clinic Arizona. First, participants will complete a questionnaire to self-assess their confidence to count carbs from food/drinks, personal perceptions on how exercise/alcohol affect their blood glucose, and how they learned about it (e.g., trial and error, education from providers), and compensation techniques used to adjust for exercise performed/alcohol consumed (for instance, adjust for basal rate or adjust insulin boluses). Stored glucose data will be analyzed for the previous 8 weeks prior to entry to establish patient-specific upper and lower bounds for determining excessive blood glucose highs and lows. Second, participants will be randomly assigned to 4 weeks of using their pump bolus wizards to decide insulin boluses and then 4 weeks of using iDECIDE to receive recommendations for insulin dosing, or vice versa. Throughout the 8 weeks, study participants will be asked to wear a wristband heart rate accelerometer that will provide data on time and duration of exercise performed. Also, during the 8 weeks, study participants will use their glucose sensor and pump to measure blood glucose and to deliver basal insulin. During the 4 weeks when participants receive recommendations from iDECIDE, the pump's bolus calculator will be turned off so participants will receive no insulin bolus recommendations from pump. While receiving recommendations from iDECIDE, participants will use the pump to manually deliver insulin boluses and can either use the advice from iDECIDE or override it.

The primary outcomes to compare iDECIDE's insulin dosing algorithm against the pump calculators will be: mean postprandial glucose level and number of events with excessive blood glucose highs and lows. Potential secondary outcomes: mean percentage of time with low glucose level and time spent in the target glucose range.
Patients receive ramucirumab IV over 30 minutes and MM-398 IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
<P>PROBLEM TO BE SOLVED: To provide an ophthalmologic composition enhanced in the effect of cooling a region to which it is applied and reduced in the initial stimulus when it is applied.  <P>SOLUTION: The ophthalmologic composition comprises (A) a monocyclic monoterpenoid and (B) a monoterpene alcohol in such amounts that 0.01 to 2,000 pts.wt. (B) is present per 1 pt.wt. (A). This composition is enhanced in the effect of cooling a region to which it is applied because the surface temperature of the region is lowered, and the cooling effect is sustained, and is reduced in the initial stimulus when it is applied, and is excellent in functionality.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Patients randomized to active arm, will consume 5ml every 12 hours per day of a suspension of probiotics (Bioflora ® Lactobacillus casei, Lactobacillus plantarum, Streptococcus faecalis y Bifidobacterium brevis) for 14 days.The content of each bottle is reconstituted up to 50 ml (10 doses) with drinking water The prescription of the intervention will be carried out and monitored through the electronic medical record. In the hospital setting, the probiotic is reconstituted by the nursing staff. If the patient is discharged before this period the patient and family will be instructed to perform the reconstitution at home.
When treating patients with creatinine clearances of less than 15 mL/min who are undergoing hemodialysis, use the dosage recommendations for patients with creatinine clearances of less than 30 to greater than or equal to 15 mL/min in Table 3 above [see Dosage and Administration ( 2.3)].  Both imipenem and cilastatin are cleared from the circulation during hemodialysis. The patient should receive Imipenem and Cilastatin for Injection (I.V.) after hemodialysis and at intervals timed from the end of that hemodialysis session. Dialysis patients, especially those with background CNS disease, should be carefully monitored; for patients on hemodialysis, Imipenem and Cilastatin for Injection (I.V.) is recommended only when the benefit outweighs the potential risk of seizures [see Warnings and Precautions ( 5.2)].
The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with a carbonyl moiety of an early glycosylation product of such target proteins resulting from their initial glycosylation. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated. The agents comprise compounds having the following structural formula: R1-CH2-R2 (I) wherein R1 is -CN, or R2 is the same as R1, or additionally can be -SO2R, R is a lower alkyl group; R3 is R, -OH, -OR, -NH2, -NHNH2, -NHR; with the proviso that when R1 and R2 are independently selected from wherein R3 is R, -OR or -NHR, then the lower alkyl portion may be an alkanediyl bridge of 1-5 carbon atoms joining the molecule into a cyclic structure; their pharmaceutically acceptable acid addition salts; and a carrier therefor. . T
PURPOSE:To provide a film-forming cosmetic, especially film-forming pack, resistant to hydrolysis with time, and having substituted storage stability, by using a copolymer of vinyl alcohol and an alkyl vinyl ether as a component. CONSTITUTION:The objective cosmetic contains the copolymer (especially having an average molecular weight of 30,000-200,000) composed of 98-80mol% (especially 95-85mol%) vinyl alcohol monomer and 2-20mol% (especially 5- 15mol%) 1-6C straight or branched chain alkyl vinyl ether monomer unit, as a main component. The content of the copolymer is preferably 1-40wt%. The cosmetic is a homogeneous paste or liquid having low viscosity, and accordingly, is can be spread easily and uniformly on the skin, and dried in a short time. USE:Film-forming agent for nail enamel, eyeliner, mascara, hair-dressing, etc., and thickener, emulsifier, binder, etc. for various cosmetics such as milky lotion, foundation, cream, face powder, shampoo, etc.
Emerging evidence suggests an association between chronic pain and elevated body fat. We sought to determine if individuals with higher body fat, measured by hip circumference (HC) and waist circumference (WC), are at risk for chronic pain when they demonstrate higher expression of inflammatory markers. We investigated the incidence and severity of pain in patients with varying WC/HC and inflammatory markers (C-Reactive Protein, IL-6, leptin) using the NIH-sponsored All of Us Database. For each inflammatory marker and sex, participants were divided into four groups based on combinations of normal/high marker levels and small/large WC/HC. We used statistical analysis to compare WC/HC and pain severity (mean NRS pain score) between groups of the same sex. In females, but not males, combinations of elevated CRP with large WC/HC exerted additive effects on the incidence of chronic pain (p < 0.01) and severe pain (p < 0.001), as well as on the severity of pain evaluated by the mean NRS pain score (p < 0.01). This relationship held true for females with high IL-6 or leptin and large WC or HC (p < 0.001 for chronic pain and severe pain incidence, and p < 0.05 for pain severity). Neither IL-6 nor leptin showed any significant impact on pain in males. Obesity status and CRP exert additive prognostic effects for chronic pain in females, but not in males. The concomitant evaluation of other inflammatory factors, such as IL-6 or leptin in females, may further augment the prediction of chronic pain. PERSPECTIVE: This article investigates the relationship between chronic pain, obesity, and inflammatory markers. It could help elucidating sex difference in pain mechanisms, as well as the risk factors for chronic pain, potentially improving patient diagnosis, follow-up and treatment.
PURPOSE:To know accurately the mutual positions among pictures in noticed regions and to ensure an integrated use of information by correcting the difference of forms of plural pictures of the same part, etc. and displaying automatically the relative position relation among pictures. CONSTITUTION:The pictures to be compared are stored in two sheets of picture memories 30 and 31. Then the memory 30 or 31 is displayed on a CRT display 32 through a processing part 33, and at the same time a reference coordinates 38 is supplied by a light pen 36. A coefficient is calculated with approximation of a polynomial. While a noticed region is designated by a light pen 37 while a specific memory is displayed on a CRT display 35 through a processing part 34. Then the corresponding coordinate value is calculated with use of a polynomial coefficient obtained at the part 33, and the noticed region is displayed. Thus the mutual positions are known accurately among pictures of the noticed region, and the information is used integratedly to the diagnosis, etc.
FIELD: chemical- -pharmaceutical industry, drugs for injection. SUBSTANCE: aerosol composition has a fluidized hydrofluoroalkane, powder-like drug dispersed in it and polymer that is soluble in indicated hydrofluoroalkane. Polymer has the repeated structural units that are alkyl-containing units and units containing carboxylic acid ester. Invention provides making an ecologically pure aerosol composition, necessary pressure, good solubility and stabilization of drugs. EFFECT: improved quality of aerosol composition. 19 cl, 1 tbl
The following information should be provided to patients receiving oxycodone and acetaminophen tablets by their physician, nurse, pharmacist, or caregiver:

  1. Do not take oxycodone and acetaminophen tablets USP if you are allergic to any of its ingredients.
  2. If you develop signs of allergy such as a rash or difficulty breathing stop taking oxycodone and acetaminophen tablets USP and contact your healthcare provider immediately.
  3. Do not take more than 4000 milligrams of acetaminophen per day. Call your doctor if you took more than the recommended dose.
  4. Patients should be aware that oxycodone and acetaminophen tablets contain oxycodone, which is a morphine-like substance.
  5. Patients should be instructed to keep oxycodone and acetaminophen tablets in a secure place out of the reach of children. In the case of accidental ingestions, emergency medical care should be sought immediately.
  6. When oxycodone and acetaminophen tablets are no longer needed, the unused tablets should be destroyed by flushing down the toilet.
  7. Patients should be advised not to adjust the medication dose themselves. Instead, they must consult with their prescribing physician.
  8. Patients should be advised that oxycodone and acetaminophen tablets may impair mental and/or physical ability required for the performance of potentially hazardous tasks (e.g., driving, operating heavy machinery).
  9. Patients should not combine oxycodone and acetaminophen tablets with alcohol, opioid analgesics, tranquilizers, sedatives, or other CNS depressants unless under the recommendation and guidance of a physician. When co-administered with another CNS depressant, oxycodone and acetaminophen tablets can cause dangerous additive central nervous system or respiratory depression, which can result in serious injury or death.
  10. The safe use of oxycodone and acetaminophen tablets during pregnancy has not been established; thus, women who are planning to become pregnant or are pregnant should consult with their physician before taking oxycodone and acetaminophen tablets.
  11. Nursing mothers should consult with their physicians about whether to discontinue nursing or discontinue oxycodone and acetaminophen tablets because of the potential for serious adverse reactions to nursing infants.
  12. Patients who are treated with oxycodone and acetaminophen tablets for more than a few weeks should be advised not to abruptly discontinue the medication. Patients should consult with their physician for a gradual discontinuation dose schedule to taper off the medication.
  13. Patients should be advised that oxycodone and acetaminophen tablets are a potential drug of abuse. They should protect it from theft, and it should never be given to anyone other than the individual for whom it was prescribed.
BACKGROUND: Aneurysmal subarachnoid hemorrhage (aSAH) is known to be triggered by several specific human activities. Sleep, by contrast, has not been considered a triggering activity for aSAH, and clinical characteristics of patients who sustain aSAH during sleep have rarely been reported in the literature.
METHODS: This is a retrospective analysis on the data acquired through a multicenter aSAH registry. Between January 2019 and December 2021, a total of 732 aSAH patients had been registered into our database. After excluding 109 patients whose activities at aSAH onset had been unidentifiable, the remaining 623 aSAH patients were dichotomized to 59 patients who sustained aSAH during sleep (Sleep group) and 564 patients who sustained aSAH during daytime activities (Awake group). Two-group comparison of demographic variables and multivariate logistic regression analysis were performed to clarify their clinical characteristics and identify potential risk factors.
RESULTS: The Sleep group exhibited significantly higher frequencies of diabetes (15.5 % vs. 6.4 %, p = 0.01) and antiplatelet use (13.8 % vs. 4.6 %, p=0.004) than the Awake group. Furthermore, multivariate logistic regression analysis showed that diabetes (OR, 3.051; 95 % CI, 1.281-7.268; p = 0.012) and antiplatelet use (OR, 3.640; 95 % CI, 1.422-9.316; p = 0.007) were correlated with aSAH occurring during sleep. There were no significant inter-group differences in the patient outcomes evaluated at discharge.
CONCLUSION: The current results indicate that risk factors may exist for aSAH occurring during sleep. Further investigations on how comorbidities such as diabetes, antiplatelet use and sleep apnea affect human hemodynamic and hemostatic parameters during sleep is warranted to better understand those relationships.
Eunkyo-san is widely used in the treatment of severe respiratory infections. Mast cells not only serve as host cells for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but also they also exacerbate Coronavirus disease in 2019 (COVID-19) by causing a cytokine storm. Here we investigated whether Eunkyo-san and its active compound naringenin regulate the expression of inflammatory cytokines and factors connected to viral infection in activated human mast cell line, HMC-1 cells. Eunkyo-san and naringenin significantly reduced levels of inflammatory cytokines including interleukin (IL)-1β, IL-6, IL-8, thymic stromal lymphopoietin, and tumor necrosis factor-α without impacting cytotoxicity. Eunkyo-san and naringenin reduced levels of factors connected to SARS-CoV-2 infection such as angiotensin-converting enzyme 2 (ACE2, SARS-CoV-2 receptor), transmembrane protease/serine subfamily member 2, and tryptase in activated HMC-1 cells. Treatment with Eunkyo-san and naringenin considerably reduced expression levels of ACE2 transcription factor, AP-1 (C-JUN and C-FOS) by blocking phosphatidylinositide-3-kinase and c-Jun NH2-terminal kinases signaling pathways. In addition, Eunkyo-san and naringenin effectively suppressed activation of signal transducer and activator of transcription 3, nuclear translocation of nuclear factor-κB, and activation of caspase-1 in activated HMC-1 cells. Furthermore, Eunkyo-san and naringenin reduced expression of ACE2 mRNA in two activated mast cell lines, RBL-2H3 and IC-2 cells. The overall study findings showed that Eunkyo-san diminished the expression levels of inflammatory cytokines and ACE2, and these findings imply that Eunkyo-san is able to effectively mitigating the cytokine storm brought on by SARS-CoV-2 infection.
PURPOSE: To obtain curing a diseased part or giving thermal effect with patching on skin and preventing lowering of sticking force with humor such as sweat, swelling of skin or generation of dermatitis for a long period of time by holding a water-permeable sticking layer on a water-absorbing carrier. CONSTITUTION: The objective patching agent is composed of (A) a carrier 2 made of water-absorbing paper or (non)woven cloth, etc., held on (B) a water- permeable sticking layer 1, patched on skin, and made of a foamed material having communicating pores of a sticking agent containing e.g. a hot-melt type polymer material. The component A is preferably composed of a supporter 5 made of a synthetic resin film, sheet or (non)woven cloth, etc., and a water- absorbing layer 4 made of water-absorbing paper or (non)woven cloth, etc. As the sticking agent of the component B, a composition composed of 5-40 pts.wt. of a hot-melt type polymer material, 5-55 pts.wt. of an alicyclic-based petroleum resin and 5-55 pts.wt. of a softener, is exemplified.
NEW MATERIAL:The compound of formula I (R<1> is lower alkyl). EXAMPLE:alpha-(N-ethyl-N-methylenecarboxy)amino-2,6-acetoxylidide hydrochloride. USE:A local anesthetic useful in operation, nerve block and pain clinic necessary for medical treatment. The anesthetic period is thrice that of the conventional anesthetic. PREPARATION:The compound of formula I can be produced by mixing and heating a compound of formula II (or its acid anhydride, active ester, acid halide, etc.) with 2,6-xylidine in the absence of solvent or in an inert solvent (e.g. chloroform, dichloroethane or THF). The compound of formula I has development and strength of anesthetic action comparable to those of lidocaine.
Patients receive pembrolizumab IV on day 1 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
First trimester vaginal bleeding is one of the most common pregnancy complications affecting 15-25% of all pregnancies. Threatened abortion is defined as bleeding through a closed cervical os in the first half of pregnancy. A subchorionic hematoma (SCH) is found in 18-39% of women with a threatened miscarriage and around 70% of women with a SCH will experience vaginal bleeding. Data on the relationship between first trimester vaginal bleeding and obstetric outcome is described mainly in retrospective and noncontrolled studies. It is hypothesized that first trimester bleeding is an indicator of a general tendency for complications (such as: preterm premature rupture of membranes (PPROM), preterm delivery (\< 37 weeks gestation; PTD) low birth weight (\<1500g; LBW) neonates, small for gestational age (SGA) neonates, placenta previa, placental abruption and stillbirth) later on in pregnancy.

Nowadays, there are not scientific based treatments for the prevention of complications associated with SCH and vaginal bleeding. Nevertheless, recent data have suggested that prophylactic administration of progesterone leads to a significant reduction in the rate of preterm deliveries and SGA neonates among patients with PTD or SGA neonates in the past. Although progesterone administration for threatened miscarriage was not studied, many physicians treat patients with first trimester vaginal bleeding with progesterone. In this era of evidence based medicine, the researchers aim to investigate whether treatment with progesterone for patients with first trimester vaginal bleeding will alter the rates of obstetrical complications and adverse pregnancy outcomes. The researchers hypothesize that treatment with progesterone for first trimester vaginal bleeding will alter the rates of the above mentioned obstetrical complications and adverse pregnancy outcomes.
Endometriosis is a chronic gynecological disorder characterized by significant chronic pelvic pain (CPP) and infertility, adversely affecting the quality of life for many women worldwide. This review aims to synthesize recent findings on natural bioactive compounds derived from various plant sources that exhibit beneficial effects in the management of endometriosis and related CPP. A thorough search of databases, including PubMed, Scopus, and Google Scholar, was conducted to identify studies evaluating the efficacy of natural compounds on endometriosis and related CPP. In alphabetical order, curcumins, ginsenosides, polyphenols and other secondary metabolites showed promising effects on oxidative stress, inflammation, and pain modulation associated with endometriosis acting on multiple pathways. Most of the selected articles were in vitro and in vivo studies in animal models, with a limited number of clinical trials. The reported natural compounds according to the highlighted multiple bioactivities, might be valuable complementary alternatives as supplements, nutraceuticals, or in advanced personalized nutrition. Further clinical investigations are needed to comprehensively evaluate their therapeutic potential, safety, efficacy and to establish effective treatment protocols.
The TASK II group will fill out a checklist about their needs and concerns, and will receive written tip sheets by mail that address the needs and concerns that they feel are most important. A nurse will call by telephone (lasting about 30 minutes or less) once a week for a total of 8 weeks, with another call at 12 weeks, to provide more information, answer questions, and to discuss more written tip sheets based on the caregiver's needs and concerns.
Four sessions are conducted with the nurses of the center assigned to the intervention group to agree on the implementation strategy together with the professionals. Once the strategy is defined, the implementation of the intervention will be launched in this group for 6 months. After this period, the final evaluation will be carried out, as well as a qualitative evaluation through a focus group.
The present invention relates to a liquid chemical formula that has the property of whitening the teeth and controlling the oral bacterial flora, with the consequent prophylactic action on caries and halitosis of bacterial origin. The active component is hydrogen peroxide (h2 o2) at a concentration of 8.25%. It also contains ethanol as a stabilizer. The formula consists of: {image-01} The main advantages of this formula are the concentration of hydrogen peroxide (8.25%) and its liquid format. Its concentration of h2 o2 (8.25%) surpasses, as a bleaching agent and bactericide, liquid formats with concentrations of h2 or2 less than 0.1%. Its liquid format gives it the possibility of exercising, throughout the oral cavity, its bactericidal activity; something that other whiteners can not do that is presented in gel format or dental strips/covers. (Machine-translation by Google Translate, not legally binding)